DIAGNOSTIC TESTING OF STDS MARKET ANALYSIS

Market Challenges And Opportunities

Social stigma associated with STDs testing

Even though prevalence of STDs is very high, out of 37.7 million people having HIV in 2020 still do not know their HIV status due to limited testing. For instance, according to a study published by Journal of the International AIDS society on November 16, 2022, a total of 96 cases were considered.  Frequency of next HIV/STI testing among those already diagnosed with an STI was 35.3% and who had symptoms with STIs was 27.1%. A few potential reasons for these observations include differences in national STI-related policies, lack of standard operation procedures, clinician-level factors, poor awareness and adherence to HIV indicator condition-guided HIV testing, and stigma associated with HIV compared to other curable STIs.

To counterbalance this restraint, an awareness programs should be conducted to eliminate stigma from society.

Reduction in funding for the treatment of STDs

Reduction in funding to fight against STDs can restrain market growth in forecast period. For instance, on June 13, 2023, The Center for Disease Control, U.S. based government organization reduced funding for workers who fight sexually transmitted infections in the U.S. states. The reduction in funding was by US$ 400 million. The spending cuts are according to recently passed debt ceiling deal.

To counterbalance this restraint, more government funding for research activities should be allocated.

Global Diagnostic Testing of STDs Market - Drivers

Increasing launch of new products in STD testing

Increasing launched of products in the field of STD testing is expected to drive the global diagnostic testing of STDs market growth over the forecast period. For instance, on January 5, 2023, Molbio Diagnostics Pvt. Ltd., an India-based molecular diagnostics company, announced it has launched Truenat HSV 1/2 for testing Herpes Simplex Virus. The test is approved by The Central Drugs Standard Control Organization (CDSCO) and can provide sample-to-test results in an hour. Truenat is a point-of-care portable, battery-operated, IoT-enabled, real-time PCR platform with a sample-to-result time of less than 1 hour. According to the company, the platform can test over 40 diseases, including COVID-19, TB, hepatitis, HIV, HPV, dengue, and malaria.

Increasing strategies like mergers and acquisitions by key market players

Increasing strategies like mergers and acquisitions by key market players is expected to drive the global diagnostic testing of STDs market growth. For instance, on March 15, 2021, F. Hoffmann- La Roche acquired GenMark Diagnostics Inc., a U.S. based molecular diagnostics company, for US$ 24.05 per share on a fully diluted basis. GenMark Diagnostics Inc., provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample GenMark’s syndromic panel testing portfolio will complement F. Hoffmann-La Roche current molecular diagnostics portfolio and the F. Hoffmann-La Roche, global network will enable expanded reach for GenMark Diagnostics Inc. products. GenMark Diagnostics, Inc., has proprietary technologies, such as ePlex and eSensor XT-8, that can be utilized by F. Hoffmann-La Roche Ltd. to develop infectious disease tests including bloodstream infections.

Global Diagnostic Testing of STDs Market: Restraints

Social stigma associated with STDs testing

Even though prevalence of STDs is very high, out of 37.7 million people having HIV in 2020 still do not know their HIV status due to limited testing. For instance, according to a study published by Journal of the International AIDS society on November 16, 2022, a total of 96 cases were considered.  Frequency of next HIV/STI testing among those already diagnosed with an STI was 35.3% and who had symptoms with STIs was 27.1%. A few potential reasons for these observations include differences in national STI-related policies, lack of standard operation procedures, clinician-level factors, poor awareness and adherence to HIV indicator condition-guided HIV testing, and stigma associated with HIV compared to other curable STIs.

To counterbalance this restraint, an awareness programs should be conducted to eliminate stigma from society.

Reduction in funding for the treatment of STDs

Reduction in funding to fight against STDs can restrain market growth in forecast period. For instance, on June 13, 2023, The Center for Disease Control, U.S. based government organization reduced funding for workers who fight sexually transmitted infections in the U.S. states. The reduction in funding was by US$ 400 million. The spending cuts are according to recently passed debt ceiling deal.

To counterbalance this restraint, more government funding for research activities should be allocated.